Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Absztrakt
Leírás
Kulcsszavak
Forrás
Journal of Medical Economics. -27 : 1 (2024), p. 109-125. -J Med Econ. - 1369-6998. - 1941-837X